136 related articles for article (PubMed ID: 36513861)
1. Genomic comparison between an in vitro three-dimensional culture model of melanoma and the original primary tumor.
Kim YS; Park M; Jin S; Jeong GH; Chung YJ; Bang CH
Arch Dermatol Res; 2023 Jul; 315(5):1225-1231. PubMed ID: 36513861
[TBL] [Abstract][Full Text] [Related]
2. Candidate therapeutic agents in a newly established triple wild-type mucosal melanoma cell line.
Shi C; Gu Z; Xu S; Ju H; Wu Y; Han Y; Li J; Li C; Wu J; Wang L; Li J; Zhou G; Ye W; Ren G; Zhang Z; Zhou R
Cancer Commun (Lond); 2022 Jul; 42(7):627-647. PubMed ID: 35666052
[TBL] [Abstract][Full Text] [Related]
3. Identification of coexistence of BRAF V600E mutation and EZH2 gain specifically in melanoma as a promising target for combination therapy.
Yu H; Ma M; Yan J; Xu L; Yu J; Dai J; Xu T; Tang H; Wu X; Li S; Lian B; Mao L; Chi Z; Cui C; Guo J; Kong Y
J Transl Med; 2017 Dec; 15(1):243. PubMed ID: 29202777
[TBL] [Abstract][Full Text] [Related]
4. Meta-Analysis and Systematic Review of the Genomics of Mucosal Melanoma.
Broit N; Johansson PA; Rodgers CB; Walpole ST; Newell F; Hayward NK; Pritchard AL
Mol Cancer Res; 2021 Jun; 19(6):991-1004. PubMed ID: 33707307
[TBL] [Abstract][Full Text] [Related]
5. Patient-derived xenograft models capture genomic heterogeneity in endometrial cancer.
Bonazzi VF; Kondrashova O; Smith D; Nones K; Sengal AT; Ju R; Packer LM; Koufariotis LT; Kazakoff SH; Davidson AL; Ramarao-Milne P; Lakis V; Newell F; Rogers R; Davies C; Nicklin J; Garrett A; Chetty N; Perrin L; Pearson JV; Patch AM; Waddell N; Pollock PM
Genome Med; 2022 Jan; 14(1):3. PubMed ID: 35012638
[TBL] [Abstract][Full Text] [Related]
6. Genomic profile of metastatic breast cancer patient-derived xenografts established using percutaneous biopsy.
Kim S; Shin D; Min A; Kim M; Na D; Lee HB; Ryu HS; Yang Y; Woo GU; Lee KH; Lee DW; Kim TY; Lee C; Im SA; Kim JI
J Transl Med; 2021 Jan; 19(1):7. PubMed ID: 33407601
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive genomic analysis of primary malignant melanoma of the esophagus reveals similar genetic patterns compared with epithelium-associated melanomas.
Li J; Liu B; Ye Q; Xiao X; Yan S; Guan W; He L; Wang C; Yu Z; Tai Z; Pei S; Ma Y; Li S; Wang Y; Wu N
Mod Pathol; 2022 Nov; 35(11):1596-1608. PubMed ID: 35688970
[TBL] [Abstract][Full Text] [Related]
8. Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436).
Nathanson KL; Martin AM; Wubbenhorst B; Greshock J; Letrero R; D'Andrea K; O'Day S; Infante JR; Falchook GS; Arkenau HT; Millward M; Brown MP; Pavlick A; Davies MA; Ma B; Gagnon R; Curtis M; Lebowitz PF; Kefford R; Long GV
Clin Cancer Res; 2013 Sep; 19(17):4868-78. PubMed ID: 23833299
[TBL] [Abstract][Full Text] [Related]
9. In-depth genomic data analyses revealed complex transcriptional and epigenetic dysregulations of BRAFV600E in melanoma.
Guo X; Xu Y; Zhao Z
Mol Cancer; 2015 Mar; 14():60. PubMed ID: 25890285
[TBL] [Abstract][Full Text] [Related]
10. Putative genomic characteristics of BRAF V600K versus V600E cutaneous melanoma.
Li Y; Umbach DM; Li L
Melanoma Res; 2017 Dec; 27(6):527-535. PubMed ID: 28858076
[TBL] [Abstract][Full Text] [Related]
11. Establishment of an orthotopic patient-derived xenograft mouse model using uveal melanoma hepatic metastasis.
Kageyama K; Ohara M; Saito K; Ozaki S; Terai M; Mastrangelo MJ; Fortina P; Aplin AE; Sato T
J Transl Med; 2017 Jun; 15(1):145. PubMed ID: 28645290
[TBL] [Abstract][Full Text] [Related]
12. BRAF(V600E) Kinase Domain Duplication Identified in Therapy-Refractory Melanoma Patient-Derived Xenografts.
Kemper K; Krijgsman O; Kong X; Cornelissen-Steijger P; Shahrabi A; Weeber F; van der Velden DL; Bleijerveld OB; Kuilman T; Kluin RJC; Sun C; Voest EE; Ju YS; Schumacher TNM; Altelaar AFM; McDermott U; Adams DJ; Blank CU; Haanen JB; Peeper DS
Cell Rep; 2016 Jun; 16(1):263-277. PubMed ID: 27320919
[TBL] [Abstract][Full Text] [Related]
13. A multidimensional impedance platform for the real-time analysis of single and combination drug pharmacology in patient-derived viable melanoma models.
Seidel D; Rothe R; Kirsten M; Jahnke HG; Dumann K; Ziemer M; Simon JC; Robitzki AA
Biosens Bioelectron; 2019 Jan; 123():185-194. PubMed ID: 30201332
[TBL] [Abstract][Full Text] [Related]
14. Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies.
Krepler C; Xiao M; Sproesser K; Brafford PA; Shannan B; Beqiri M; Liu Q; Xu W; Garman B; Nathanson KL; Xu X; Karakousis GC; Mills GB; Lu Y; Ahmed TA; Poulikakos PI; Caponigro G; Boehm M; Peters M; Schuchter LM; Weeraratna AT; Herlyn M
Clin Cancer Res; 2016 Apr; 22(7):1592-602. PubMed ID: 26673799
[TBL] [Abstract][Full Text] [Related]
15. Systematic review and meta-analysis of genomic alterations in acral melanoma.
Broit N; Johansson PA; Rodgers CB; Walpole ST; Hayward NK; Pritchard AL
Pigment Cell Melanoma Res; 2022 May; 35(3):369-386. PubMed ID: 35229492
[TBL] [Abstract][Full Text] [Related]
16. Comparative study on driver mutations in primary and metastatic melanomas at a single Japanese institute: A clue for intra- and inter-tumor heterogeneity.
Kaji T; Yamasaki O; Takata M; Otsuka M; Hamada T; Morizane S; Asagoe K; Yanai H; Hirai Y; Umemura H; Iwatsuki K
J Dermatol Sci; 2017 Jan; 85(1):51-57. PubMed ID: 27771229
[TBL] [Abstract][Full Text] [Related]
17. Hybrid Capture-Based Genomic Profiling Identifies BRAF V600 and Non-V600 Alterations in Melanoma Samples Negative by Prior Testing.
Boussemart L; Nelson A; Wong M; Ross JS; Sosman J; Mehnert J; Daniels G; Kendra K; Ali SM; Miller VA; Schrock AB
Oncologist; 2019 May; 24(5):657-663. PubMed ID: 30683711
[TBL] [Abstract][Full Text] [Related]
18. Performance comparison of three BRAF V600E detection methods in malignant melanoma and colorectal cancer specimens.
Løes IM; Immervoll H; Angelsen JH; Horn A; Geisler J; Busch C; Lønning PE; Knappskog S
Tumour Biol; 2015 Feb; 36(2):1003-13. PubMed ID: 25318602
[TBL] [Abstract][Full Text] [Related]
19. Drug responses are conserved across patient-derived xenograft models of melanoma leading to identification of novel drug combination therapies.
Ice RJ; Chen M; Sidorov M; Le Ho T; Woo RWL; Rodriguez-Brotons A; Luu T; Jian D; Kim KB; Leong SP; Kim H; Kim A; Stone D; Nazarian A; Oh A; Tranah GJ; Nosrati M; de Semir D; Dar AA; Chang S; Desprez PY; Kashani-Sabet M; Soroceanu L; McAllister SD
Br J Cancer; 2020 Mar; 122(5):648-657. PubMed ID: 31857724
[TBL] [Abstract][Full Text] [Related]
20. [Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation].
Lázár V
Magy Onkol; 2013 Jun; 57(2):96-9. PubMed ID: 23795354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
